Shorter courses of radiation therapy may be in order for women with early-stage breast cancer. And the largest study to test this suggests the abbreviated treatment time in no way affects risk of recurrence.

Often, the greatest hassle of radiation is getting to and from appointments, every weekday, for many weeks. With less frequent visits, life could get a whole lot easier.

Dr. John Dewar of the University of Dundee in Scotland led a two-part study of nearly 4,500 women in the United Kingdom to test courses of radiation and found five years later that cancer recurrences were low -- about two to five percent -- for women who received both longer and shorter durations of therapy. There were so few recurrences -- 158 -- that doctors believe the treatments are equivalent. They just can't say this with certainty yet.

This is great news for patients traveling great distances to their treatment facilities. Other benefits of shorter radiation timelines are less swelling and shrinkage of breast tissue and less enlargement of blood vessels.

I love it when I find research coming straight from the halls of the very hospital where I received my breast cancer treatment. It reminds me that I'm in good hands, that University of Florida researchers are on the cusp of breaking through the mysteries of cancer, that I may one day be the lucky recipient of cutting-edge discoveries, like this:

University of Florida researchers report in a paper to be published in the August issue of Stem Cells that bone marrow stem cells attracted to the site of cancerous growths often take on the appearance of the malignant cells surrounding them. While these cells look like cancer, though, they may not act like cancer. They have the same skin, says lead study author Dr. Chris Cogle. But the question is: do they have the same guts?

"Our results indicate these cells act as developmental mimics; they come in and look like the surrounding neoplastic tissue, but they aren't actually the seed of cancer," said Cogle who is affiliated with the cancer center I've called home for more than two years.

I have heard many times that being obese or overweight increases the risk of developing breast cancer. It also has been said that it shortens the time between the return of the disease.

Why is this? It might be because of a hormone in our bodies called leptin.

Researchers are doing experiments on mice that might prove to be an important influence in developing drugs that target the mechanism that causes obese individuals to have a higher risk of the disease.

Italian researchers speaking at the Experimental Biology 2007 in Washington, DC, report evidence on how leptin, a hormone found in fat cells, significantly influences breast cancer development and progression in mice.

Leptin sends messages to the body that no more food is needed, a process that might not work well for those that are overweight or obese. Leptin also is involved with cell differentiation and proliferation in the body. Leptin has demonstrated to play a significant role in promoting breast cancer in obese women by increasing the amount of estrogen in the breast tissue.

Even though these are experiments done only on mice at this point, this learning process is what leads to new drugs and targeted therapies.

New hope may be an injection away for patients living with glioma, a terminal brain cancer that comes with a life expectancy of about 25 weeks post-diagnosis.

A new vaccine called Vitaspen is made by using tissue extracted from each person's cancerous tumor. The tissue is used as a unique footprint for the vaccine that targets destructive tumor tissue while sparing healthy tissue in the same region.

Vitaspen is only in the first stage of clinical human trials, but researchers are pleased with the promise of the new drug -- particularly the benefits trial participants are gaining form the treatment. They have reported no adverse side effects, and the drug has increased the overall survival rate.

Results of stage one trials will determine if the drug warrants stage two testing.

Cancer is a complicated disease often described by those who know it well in confusing medical, technical, and scientific terms. There's a way to understand it in simple terms, though. And a recent CBS news story features a great run-down on the disease, its causes, how it grows, and more.

Think about this:

• Cancer refers to any one of a large number of diseases characterized by the uncontrollable growth of abnormal cells. These cells have the ability to infiltrate and destroy normal tissue and can spread -- metastasize -- throughout the body.

• Cancer is caused by damage in the DNA. DNA is like a set of instructions for cells and tells cells how to grow and divide. Normal cells can develop mutations in their DNA but can repair most of them. If they cannot make a repair, the cells often die. But certain mutated cells don't repair and don't die. They instead grow and become cancerous.

• Normal, healthy cells grow in an orderly, well-controlled way. They live for a set period of time and then die on schedule. Dead cells are replaced by new normal cells. Cancer cells, in contrast, grow in an uncontrolled manner. They don't die. They accumulate. One malignant cell becomes two, two become four, four become eight, and so on, until a mass of cells -- a tumor -- is created. Tumors remain small until they're able to attract their own blood supply, which allows them to obtain the oxygen and nutrients they need to grow larger.

• Not all cancers form tumors. Leukemia, for example, is a cancer of the blood, bone marrow, lymphatic system, and spleen.
  
  
• Cancer can take decades to develop. By the time a cancerous mass is detected, it's likely that 100 million to one billion cancer cells are present, and the original cancer may have been dividing for five years or more.

• Lung cancer is the top cancer killer among men and women and will kill 160,390 people in 2007.

In the April issue of the journal Radiology, researchers published a report that says they have used adult bone marrow stem cells to regenerate healthy human liver tissue.

When cancer invades the liver sometimes it is impossible to have surgery performed to remove the tumor. This is because there is not enough healthy liver left behind to support the body. These stems cells help to regenerate the healthy portion of the liver so surgery can be performed.

Gunther Furst, M.D, coauthor and professor of radiology, says "Our study suggests that liver stem cells harvested from the patients own bone marrow can further augment and accelerate the liver's natural capacity to regenerate itself."

The doctor who read my mammogram and ultrasound results today is the same doctor who detected in my recent MRI something of unknown significance. Today, the unknown remains. But the significance is not so significant.

This doctor saw an unusual pattern of tissue in my right breast when she viewed my Friday MRI results, some sort of enhancement she didn't see in the left breast or on the MRI I had a year ago. But today's mammogram looked good and today's ultrasound did too. So I guess if three different imaging tests don't turn up anything truly suspicious and there doesn't appear to be anything to biopsy, then all is well. For now.

All that must be determined now is when I will report back for more screening to chart the state of the dense breast tissue that keeps me on my toes.

Another bullet dodged. Another day in the life of a worried breast cancer girl.

A sarcoma is a cancer of the connective or supportive tissue and soft tissue affecting the bones, cartilage, fat, muscle, and blood vessels. Osteogenic sarcoma or osteosarcoma is one of the most common childhood bone cancers. Soft tissue sarcomas are more common in adults than in children. In all, sarcomas constitute fewer than 1 percent of all cancers. Its treatment is made more difficult with the existence of more than 70 varieties.

New studies released by the Journal of the National Cancer Institute showed that children who survive cancers have an increased risk of developing a secondary sarcoma,compared with the general population. Tara Henderson, M.D., of the University of Chicago Department of Pediatrics, and colleagues examined the incidence of secondary sarcomas and the risk factors associated with that risk among the 14,372 participants in the Childhood Cancer Survivor Study. Overall, there were 751 second cancers diagnosed among the participants, 108 of which were secondary sarcomas such as soft tissue sarcoma, malignant peripheral nerve sheath tumors, and osteosarcoma. These sarcomas were diagnosed an average of 11 years after patients were diagnosed with their primary cancer.

Women with early stage breast cancer now have a new tool at their disposal. The tool -- called MammaPrint -- is newly approved by the FDA and while it is not yet a perfect measure, it can be used along with other information to estimate whether breast cancer is likely to return in five or 10 years.

The value of this test, that measures through computer analysis the activity of 70 genes using a sample of tissue removed from a breast tumor, is that doctors and patients can better determine course of treatments.

MammoPrint offers two results -- high risk and low risk -- and accurately picked in studies which women were at low risk at least 90 percent of the time. However, for women who were told they were at high risk for recurrence as a result of the test, just 23 percent experienced a relapse.

"You can't go all the way to the bank with this test," says FDA official Dr. Steven Gutman who argues the test is still better than having no information at all.

Agendia, the Dutch maker of MammoPrint, is exploring ways to make this one-of-a-kind product available in the United States. It has been used in the Netherlands since 2005.

"This test has enormous implications for the short-term future of cancer research in general, and is one of the truly great breakthroughs of our time," says Cancer Blog reader Gregory Pawelski with whom I am grateful for sharing this story tip with me.

Cancer-related fear once consumed my mind. Now it sits lodged in the back of my brain and only presents itself on rare occasions.

I handle my fears so much better now than when cancer was new and fresh and raw. My fears hardly ever cause me real anxiety, they don't cripple my mental functioning anymore, and more than ever, they serve to focus my efforts in life. When fear strikes, it's usually a wake-up call of sorts, a reminder to leave no stone unturned, a summons to keep on living.

Although so much less threatening than they once were, my fears still exist. And I like to review them once in awhile, lose myself in a little emotional housekeeping, tidy up some of the mess cancer made. I always feel better when things are in order -- fears included.

• I fear a breast cancer recurrence, the return of a tumor that rises to the surface of my skin and presents itself again underneath my fingertips -- or in my worst-case scenario is lost among dense breast tissue, undetected by self-exam, and caught too late by some combination of mammogram, ultrasound, and MRI.

• I fear more than anything another cancer -- something entirely different from breast cancer, something buried in my body and not as responsive as breast cancer to treatment. I am prepared for a second visit from breast cancer because I know how to proceed, know I will succumb to treatment that is familiar, know I will remove both breasts in the most radical of life-saving approaches. But cancer in my lungs, brain, bones, blood, ovaries is out of my realm. And these cancers -- among many others -- really scare me.
  

• I fear that my mom and my sister -- my first-degree female relatives -- will one day follow in my breast cancer footsteps. I once thought family history trickled down from above, from older family members. Now I know the disease can start with anyone. I am the anyone in my family. I am the reason my mom and sister are closely watched and monitored and tested. I am the one that put the fear of cancer into their hearts and minds -- and into mine.
  

• I fear having another baby. I fear the return of cancer during pregnancy, leaving me with difficult choices regarding my health and my baby's health. I fear cancer returning after a baby is born, leaving me with one more child and more treatment to manage. I fear another cancer would lead to a decreased chance of survival and another baby would leave my husband feeling stranded should I die too soon. And I fear having a baby girl who would inherit the very real chance of developing breast cancer at some time during her life.
  

• I fear not having another baby. I fear the regret I may feel one day, perhaps 50 years from now when I am healthy and cancer-free and without the child I longed for. I fear I am being overly cautious, too tentative, a bit selfish. A fellow cancer survivor once wrote me, "I learned that my family continues, even if I do not. I also learned that they are at least as tough as I am so will cope with the genes I pass to them and their own cancer battles if needed. Finally, I learned they look out for each other just as I looked out for them. No matter what your future, you will never regret giving another child a place in your family." I fear this man may be right.
  

• I fear dying at a young age. I fear leaving my children before they are grown. I fear leaving my husband a single parent, my mom someone who has lost a child, and my sister an only child. I have been told over and over again that my chances of survival are great, fantastic even. I have a 93 percent chance of not dying from breast cancer. This does seem great -- until I take into account that this percentage is good for only five years. My five years will expire when I am 39 years old. What happens then, I am not sure. The only thing I am sure about is that five years is not enough time. I want more, need more, demand more. Yet I fear my days may be numbered.
  

These are the fears that keep me focused. And while they are sometimes not-so-pleasant, I am in no hurry to resolve any of them. I am thankful really to have these fears swirling in my head -- because it means I am alive. And for me, being alive with fears is better than not being alive at all.

In a radical new approach to attacking cancer, researchers will soon attempt to kill tumors by infecting them with viruses that cause ailments like the common cold.

This virus therapy treatment -- considered the third pillar alongside chemotherapy and radiation -- could one day become standard battle against cancer.

One Belfast doctor says anything that could improve the lives of cancer patients is worth a try. And try is exactly what Leonard Seymour, Professor of Gene Therapy at Oxford University, plans to do when he begins leading trials later this year.

Seymour, who has been working with viruses that kill cancer cells while sparing healthy tissue, will use a stealth virus masked from the body's immune system with a polymer coat that could travel through the bloodstream and reach tumors.

Two viruses are likely candidates for study in the first clinical trials -- adenovirus, cause of a cold-like virus, and vaccinia, cause of cowpox and a component in the smallpox vaccine.

Preliminary research on mice shows that virus therapy works well on tumors resistant to standard cancer drugs. But several years of trials will be necessary before the therapy can be considered for use on all cancers.

Cancer of the esophagus is one of the fastest rising cancers in the United States -- but the common screening test, both expensive and risky, is not widely used. Thankfully, a newer option, around since the mid-90s, is quicker and easier and is catching on around the country.

Trans-Nasal Esophagoscopy (TNE) is the better option, and it works like this: a doctor numbs the nose, inserts a thin, flexible tube -- no bigger than a pencil -- through the nostril and into the esophagus, removes a bit of tissue for biopsy purposes, takes a few pictures, and pulls the tube back out through the nostril. The patient gets to watch it all on a monitor and gets to depart from the procedure with no ill effects.

Traditional esophagus cancer screening involves a similar tube that is inserted through the mouth. Due to the gag reflex, patients are sedated. While there are often no complications from the procedure itself, the intravenous sedation can cause problems.

"You don't need those risks to see what's going on," says one doctor, who reports that esophageal cancer responds very well when caught early by tools like TNE.

The technique, known as radioembolization or intra-arterial brachytherapy, uses the vascular system to deliver targeted treatment to the tumor. The tiny glass bubbles filled with radioactive material deliver high doses of tumor-killing radiation directly to the liver tumors.

Liver tumors use a supply of blood that is largely separate from the blood that nourishes normal liver tissue, so very few of the bubbles end up in the healthy liver.

The bubbles are smaller than the diameter of a human hair. The outpatient procedure takes about an hour to complete. The bubbles release over 10-14 days.

Patients may be candidates for this procedure if they are not able to get a liver transplant. Mayo Clinic radiation oncologists are now using this procedure.

Tampa's H. Lee Moffitt Cancer Center & Research Institute, the only comprehensive cancer center in Florida, has just partnered with Merck & Co., one of the world's largest drug companies, to develop personalized cancer treatments using a patient's genetic profile.

The two powerhouse entities will form a for-profit company called M2Gen on donated land near the University of South Florida. And in the span of just a few years, researchers plan to compile a database of tumor tissue and other medical information to determine why some patients respond to treatment while others do not. The database could house information on more than 30,000 patients within five years and will enable researchers to identify biological markers that could help doctors choose the most effective treatment based on the genetic make-up of each patient's tumor.

Blind treatment -- where everyone receives the same thing -- will be a thing of the past as tailor-made therapies replace the one-size-fits-all approach.

Florida Governor Jeb Bush says of the partnership that will create more than 170 high-paying jobs, "Man, I don't know if you can think of a better Christmas present than that."

The National Institutes of Health (NIH) has awarded Techniscan Medical Systems (TMS), a Utah-based company that has developed an ultrasound imaging system known as UltraSound CTTM, a $2.8 million dollar small business grant to go forward with a radiation-free, non-invasive, breast cancer screening device that does not compress the breast during examination.

How does it work? While a woman is lying face down, the breast is suspended in warm water and an ultrasound scanner rotates in a circle, producing detailed 3-D images. According to the company, the diagnostic imaging tool will be able to detect normal, benign and malignant tissues in the breast.

To learn more about the UltraSound CTTM, visit the TMS website.